SciClone Pharmaceuticals (Holdings) Ltd
HKEX:6600
Intrinsic Value
SciClone Pharmaceuticals (Holdings) Ltd. is an investment holding company which manufactures and markets immune and oncology pharmaceutical products. [ Read More ]
The intrinsic value of one SciClone Pharmaceuticals (Holdings) Ltd stock under the Base Case scenario is 28.18 HKD. Compared to the current market price of 17.98 HKD, SciClone Pharmaceuticals (Holdings) Ltd is Undervalued by 36%.
Valuation Backtest
SciClone Pharmaceuticals (Holdings) Ltd
Run backtest to discover the historical profit from buying and selling SciClone Pharmaceuticals (Holdings) Ltd stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
SciClone Pharmaceuticals (Holdings) Ltd
| Current Assets | 3.4B |
| Cash & Short-Term Investments | 2B |
| Receivables | 868m |
| Other Current Assets | 582.5m |
| Non-Current Assets | 553.1m |
| Long-Term Investments | 110.6m |
| PP&E | 39.4m |
| Intangibles | 396m |
| Other Non-Current Assets | 7m |
| Current Liabilities | 698.2m |
| Accounts Payable | 623.1m |
| Other Current Liabilities | 75.1m |
| Non-Current Liabilities | 36.9m |
| Long-Term Debt | 19.8m |
| Other Non-Current Liabilities | 17.2m |
Earnings Waterfall
SciClone Pharmaceuticals (Holdings) Ltd
|
Revenue
|
3.2B
CNY
|
|
Cost of Revenue
|
-799.4m
CNY
|
|
Gross Profit
|
2.4B
CNY
|
|
Operating Expenses
|
-1.2B
CNY
|
|
Operating Income
|
1.2B
CNY
|
|
Other Expenses
|
-83.2m
CNY
|
|
Net Income
|
1.1B
CNY
|
Free Cash Flow Analysis
SciClone Pharmaceuticals (Holdings) Ltd
Profitability Score
Profitability Due Diligence
SciClone Pharmaceuticals (Holdings) Ltd's profitability score is 84/100. The higher the profitability score, the more profitable the company is.
Score
SciClone Pharmaceuticals (Holdings) Ltd's profitability score is 84/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
SciClone Pharmaceuticals (Holdings) Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Score
SciClone Pharmaceuticals (Holdings) Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
SciClone Pharmaceuticals (Holdings) Ltd
According to Wall Street analysts, the average 1-year price target for SciClone Pharmaceuticals (Holdings) Ltd is 16.17 HKD with a low forecast of 13.84 HKD and a high forecast of 18.9 HKD.
Shareholder Return
Price
SciClone Pharmaceuticals (Holdings) Ltd
| Average Annual Return | -24.72% |
| Standard Deviation of Annual Returns | 41.02% |
| Max Drawdown | -68% |
| Market Capitalization | 11.3B HKD |
| Shares Outstanding | 600 541 160 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
SciClone Pharmaceuticals (Holdings) Ltd. is an investment holding company which manufactures and markets immune and oncology pharmaceutical products. The company is headquartered in Shanghai, Shanghai and currently employs 890 full-time employees. The company went IPO on 2021-03-03. The firm primarily engages in the sales of its proprietary product, Zadaxin, its in-licensed products and promotion products on behalf of its business partners in China.
Contact
IPO
Employees
Officers
The intrinsic value of one SciClone Pharmaceuticals (Holdings) Ltd stock under the Base Case scenario is 28.18 HKD.
Compared to the current market price of 17.98 HKD, SciClone Pharmaceuticals (Holdings) Ltd is Undervalued by 36%.
You don't have any saved screeners yet
